Travere Therapeutics, Inc. TVTX Total costs & expenses
Total costs & expenses at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostsAndExpenses.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s total costs & expenses?
- Travere Therapeutics, Inc. (TVTX) reported total costs & expenses of $164.11M in Q1 2026.
- How has Travere Therapeutics, Inc.'s total costs & expenses changed year-over-year?
- Travere Therapeutics, Inc.'s total costs & expenses increased by 31.9% year-over-year, from $124.41M to $164.11M.
- What is the long-term trend for Travere Therapeutics, Inc.'s total costs & expenses?
- Over 4 years (2021 to 2025), Travere Therapeutics, Inc.'s total costs & expenses has grown at a 13.7% compound annual growth rate (CAGR), from $331.26M to $553.55M.
- What does total costs & expenses mean?
- This metric aggregates all operating and non-operating costs incurred by the company to support its business activities, including research, development, and administrative functions. It serves as a comprehensive measure of the company's total burn rate and operational efficiency. Investors use this to evaluate the company's ability to manage its cost structure relative to its revenue generation and strategic growth objectives.